Lidocaine as an Antiarrhythmic: Sodium Channels and Ventricular Rhythms
Lidocaine is a class Ib antiarrhythmic. It blocks voltage-gated sodium channels and has important effects in ventricular tissue. The channel’s state and the tissue’s condition affect how it works, so understanding the rhythm comes before deciding whether the drug fits.
Sachi, CRNA
CRNA

In This Article (8 sections)
As you learn the antiarrhythmic classes, give the channel state a little attention too. It helps you explain more than which list lidocaine belongs on.
The antidysrhythmic lessons in the CRNA Club cardiac learning library through the seven-day platform trial help you connect the electrical problem with the patient’s circulation. Start there rather than treating “fast rate” as a diagnosis.
What does class Ib mean?
Class I antiarrhythmics act on sodium channels. The subgroups differ in how they bind and what they do to the cardiac action potential, the electrical change across a heart cell’s membrane.
Lidocaine binds preferentially to inactivated sodium channels and dissociates relatively quickly. Inactivated means the channel isn’t yet available for another activation. Dissociation means the drug lets go of the channel.
Sodium entry helps produce rapid depolarization in working atrial and ventricular muscle. When lidocaine blocks susceptible channels, it reduces excitability and changes conduction in that tissue. The 2026 FDA lidocaine antiarrhythmic label describes its predominant inactivated-channel blockade and ventricular electrical effects.
Identify the actual rhythm before deciding whether sodium-channel blockade fits the problem.
Why does ischemic tissue respond differently?
Sodium channels move between resting, open and inactivated states. Their availability changes with rate and membrane potential, the electrical difference across the cell membrane.
A drug that favors one channel state won’t act identically in healthy resting tissue and depolarized or ischemic ventricular tissue. The starting tissue condition changes which channels are available for it to interact with.
In the cardiac pharmacology lessons, follow the tissue condition into channel behavior and then the electrical effect. Compare that with a beta blocker used to slow AV-nodal conduction. They aren’t doing the same job.
Does lidocaine treat any fast rhythm?
No. Sinus tachycardia, atrial fibrillation, reentrant SVT and ventricular tachycardia have different mechanisms. A fast monitor rate alone doesn’t tell you lidocaine is appropriate.
It has a role in the appropriate VF or pulseless-VT cardiac-arrest pathway. When a patient has a pulse, rhythm and stability still determine the strategy. The 2025 AHA adult advanced life-support guidance separates those situations.
If electrical treatment is indicated for an unstable, life-threatening rhythm, medication doesn’t replace it.
What should you check before discussing the drug?
Use the patient and tracing together:
- Check for a pulse and assess stability.
- Name the rhythm, beyond “tachycardia.”
- Look for reversible causes, including ischemia and electrolyte problems.
- Match treatment with the rhythm and current pathway.
- Reassess rhythm, perfusion and adverse effects after intervention.
That sequence helps you explain when a familiar medication would miss the actual problem.
What do two fast-rate examples show?
In these fictional cases, Patient A has sinus tachycardia while bleeding. Patient B has recurrent ventricular arrhythmia with ischemia. Both have a fast rate, but you need different explanations.
For Patient A, suppressing the rate without addressing the bleeding misses why the circulation is struggling. Patient B needs assessment of the ventricular electrical instability through the appropriate arrhythmia pathway. You still need the exact rhythm and stability before choosing treatment.
“Lidocaine treats tachycardia” can’t tell you what to do in either case. The rhythm, cause and condition of the patient give that statement the detail it’s missing.
What toxicity and product checks matter?
Excess systemic lidocaine can cause neurological and cardiovascular toxicity. New neurological symptoms, seizures, conduction changes or circulatory deterioration need prompt assessment. Add up exposure from different procedural uses too.
The sodium-channel mechanism is shared with lidocaine’s local-anesthetic action. The formulation, indication, route and monitoring aren’t interchangeable. Verify the actual product before IV antiarrhythmic use rather than assuming any local-anesthetic preparation is suitable.
Our Final Thoughts
Choose one of the fast-rate examples and explain the electrical problem before mentioning lidocaine. Then compare it with the other case. If the channel-state terms still feel unfamiliar, go back to what “inactivated” means and build from there.
Continue your cardiac pharmacology review
Use the seven-day CRNA Club platform trial for cardiac lessons and questions. Practice explaining a drug-rhythm match and a mismatch, including the patient’s stability.


